Differences in radiosensitivity between three HER2 overexpressing cell lines-Reference-Cited by-同舟云学术

Differences in radiosensitivity between three HER2 overexpressing cell lines

Published:2008-01-12 Issue:6 Volume:35 Page:1179-1191
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Steffen Ann-Charlott,Göstring Lovisa,Tolmachev Vladimir,Palm Stig,Stenerlöw Bo,Carlsson Jörgen

Publisher

Springer Science and Business Media LLC

Subject

Radiology Nuclear Medicine and imaging,General Medicine,Radiology Nuclear Medicine and imaging,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00259-007-0713-x.pdf

Reference40 articles.

1. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005;23(9):1147–57.

2. DeNardo SJ, DeNardo GL. Targeted radionuclide therapy for solid tumors: an overview. Int J Radiat Oncol Biol Phys 2006;66(2 Suppl):S89–95.

3. Goldenberg DM, Sharkey RM. Advances in cancer therapy with radiolabeled monoclonal antibodies. Q J Nucl Med Mol Imaging 2006;50(4):248–64.

4. O’Donoghue JA, Bardies M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 1995;36(10):1902–9.

5. Carlsson J, Forssell AE, Hiet-ala SO, Stigbrand T, Tennvall J. Tumour therapy with radionuclides: assessment of progress and problems. Radiother Oncol 2003;66:107–17.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular subtypes of breast cancer predicting clinical benefits of radiotherapy after breast-conserving surgery: a propensity-score-matched cohort study;Breast Cancer Research;2023-12-08

2. A Review on Tumor Control Probability (TCP) and Preclinical Dosimetry in Targeted Radionuclide Therapy (TRT);Pharmaceutics;2022-09-22

3. Experimental Therapy of HER2-Expressing Xenografts Using the Second-Generation HER2-Targeting Affibody Molecule 188Re-ZHER2:41071;Pharmaceutics;2022-05-20

4. Affibody-mediated PNA-based pretargeted co-treatment improves survival of trastuzumab-treated mice bearing HER2-expressing xenografts;Journal of Nuclear Medicine;2021-10-28

5. In vitro Study of Radiosensitivity Effects of Galbanic Acid on Ovarian Tumor Cells (OVCAR-3 Cell Line);Natural Product Communications;2021-10